Melane Sampson, Author at BioTuesdays

Developments

Oncotelic moving closer to commercial launch of AI-enabled robotics

Oncotelic Therapeutics (OTCQB: OTLC) has announced an update on the advancement of its proprietary AI platform and robotic integration toward commercialization, following the integration of approximately 28 million...

April 30, 2026

Executive Moves

Piper Sandler adds Dr. Patrick McCormick to healthcare investment banking team

Investment bank, Piper Sandler, has announced the appointment of Patrick McCormick, MD, as a managing director in its healthcare investment banking group. Dr. McCormack will be based in San Francisco and focused on...

April 30, 2026

Executive Moves

Kunal Bhatia joins Strand as CFO

Closely held Strand Therapeutics has announced the appointment of Kunal Bhatia as chief financial officer (CFO). Mr. Bhatia brings 15 years of investment banking experience leading fundraising, business development, and...

April 30, 2026

Markets

Tivic rebrands as Valion Bio and changes ticker, closes down 28%

After changing its name from Tivic Health Systems (NASDAQ: TIVC) to Valion Bio (NASDAQ: VBIO), effective at market open today, the company’s stock price declined 28% to close at $1.01, after trading as low as $0.865...

April 28, 2026

Developments

USPTO issues NoA to Nuwellis for catheter technology

Nuwellis (NASDAQ: NUWE) has announced that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance (NoA) for a new patent covering its novel dual-lumen midline catheter technology designed for use...

April 28, 2026

Developments

VivoSim intestinal model combined with AI predicts drug-induced diarrhea without animal testing

VivoSim Labs (NASDAQ: VIVS) has announced the availability of an AI prediction tool leveraging its NAMkind intestinal models to accurately predict the potential of a drug to cause diarrhea in patients, eliminating...

April 28, 2026

Feature

Niagen Bioscience innovating NAD+-based therapies from healthy aging to pediatric orphan diseases

Niagen Bioscience (NASDAQ: NAGE) is pioneering the research and development of nicotinamide adenine dinucleotide (NAD+)—a vital coenzyme essential to cellular metabolism, energy production, and DNA repair that declines...

April 28, 2026

Developments

Alto launches Phase 2b trial of ALTO-207 in TRD

Alto Neuroscience (NYSE: ANRO) has initiated its Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study...

April 27, 2026

Developments

FDA grants Immutep ODD for efti in STS

Immutep (NASDAQ: IMMP) has announced that the FDA has granted orphan drug designation (ODD) for eftilagimod alfa (efti) for the treatment of soft tissue sarcoma (STS), a rare cancer with significant unmet medical need...

April 27, 2026

Developments

Clearmind reports positive topline results from CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND) has announced that CMND-100, the company’s proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of alcohol use disorder (AUD), has met the primary endpoint in...

April 27, 2026

Author - Melane Sampson

Oncotelic moving closer to commercial launch of AI-enabled robotics

Piper Sandler adds Dr. Patrick McCormick to healthcare investment banking team

Kunal Bhatia joins Strand as CFO

Tivic rebrands as Valion Bio and changes ticker, closes down 28%

USPTO issues NoA to Nuwellis for catheter technology

VivoSim intestinal model combined with AI predicts drug-induced diarrhea without animal testing

Niagen Bioscience innovating NAD+-based therapies from healthy aging to pediatric orphan diseases

Alto launches Phase 2b trial of ALTO-207 in TRD

FDA grants Immutep ODD for efti in STS

Clearmind reports positive topline results from CMND-100 trial in AUD

Subscribe